Evidence map›Paper›PMID 33839882›Full record

Trial reportAnnals of hematology2021

Cereblon expression is a prognostic marker in newly diagnosed POEMS syndrome treated with lenalidomide plus dexamethasone.

Qian-Qian Cai, Xue-Min Gao, Jing Le, Hao Zhao, Hao Cai, Xin-Xin Cao, Jian Li

Abstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Annals of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Qian-Qian CaiDepartment of Hematology, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, 315040, Zhejiang, China.
Xue-Min GaoDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Jing LeDepartment of Hematology, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, 315040, Zhejiang, China.
Hao ZhaoDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Hao CaiDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Xin-Xin CaoDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Jian LiDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. LiJian@pumch.cn.ORCID http://orcid.org/0000-0002-4549-0694
Chinese Academy of Medical Sciences & Peking Union Medical College · CNNingbo University · CN

Funding

Natural Science Foundation of Ningbo 2019A610275
6 · The paper itself

Abstract

POEMS syndrome is a rare plasma cell disorder. Lenalidomide has recently emerged as a therapeutic option for POEMS syndrome. Cereblon has been identified as the direct target of lenalidomide, and high cereblon expression is associated with better response and outcome to lenalidomide therapy in multiple myeloma patients. Here, we analyzed the predictive value of cereblon, IKZF1, and IKZF3 in CD138

Indexed as

Adaptor Proteins, Signal TransducingAdultAgedAnti-Inflammatory AgentsBiomarkers, TumorDexamethasoneFemaleGene ExpressionHumansImmunologic FactorsLenalidomideMaleMiddle AgedPOEMS SyndromePrognosisProspective StudiesAdaptor Proteins, Signal TransducingAnti-Inflammatory AgentsBiomarkers, TumorCRBN protein, humanDexamethasoneImmunologic FactorsLenalidomideRNA, MessengerUbiquitin-Protein LigasesCereblonIKZF1IKZF3LenalidomidePOEMS syndrome

Identifiers

PMID33839882
OpenAlexW3153035273

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.